Annals of the New York Academy of Sciences
August 1, 2006
Filippo Sean Giorgi, Gloria Lazzeri, Gianfranco Natale et al.
33 citations
Abstract: In the past decades, there was a massive increase in the abuse of methylenedioxymethamphetamine (MDMA) in the Western countries. Seizure onset after MDMA is considered to be related mainly to its acute systemic effects (e.g., hyponatremia and hyperthermia). However, additional mechanisms might concur to it as well. Experiments aimed at disclosing the basis for such an acute effect...
Annals of the New York Academy of Sciences
August 1, 2006
Ilaria Tamburini, Fabio Blandini, Marco Gesi et al.
24 citations
Abstract: Several studies, carried out in chronic (+/−) 3,4‐methylenedioxymethamphetamine (MDMA) abusers, have shown memory loss and cognitive impairment, as well as persistent electroencephalographic changes. This suggests that, at least in humans, forebrain areas, including the limbic system, might be altered by MDMA. Consistently, recent experimental evidences suggest that, in rodents, MDMA,...
Microscopy research and technique
July 1, 2004
Marco Gesi, Michela Ferrucci, Mario Giusiani et al.
The neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) has been intensely investigated due to the widespread abuse of this drug and its neurotoxic effects. In mice, MDMA neurotoxicity has been demonstrated for striatal dopamine (DA) terminals. However, the current literature has reported great variability in the effects induced by MDMA; this is partially due to changes in...
Synapse
2001
Francesco Fornai, Filippo Sean Giorgi, Marco Gesi et al.
54 citations
Previous studies reported that drugs acting as monoamine oxidase (MAO)-B inhibitors prevented biochemical effects induced by the neurotoxins N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) and 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). In this study, we administered DSP-4 (50 mg/kg) or MDMA (50 mg/kg x 2, 2 h apart) to MAO-B deficient mice. Monoamine content in various brain...